- In June 2024, AbbVie announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis. This makes it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.
- In April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis. The approval also covers adults with acute bacterial skin and skin structure infections (ABSSSI) and pediatric patients aged three months to under 18 years with community-acquired bacterial pneumonia (CABP).
- In April 2024, Pfizer Inc. announced that the European Commission (EC) had granted marketing authorization for EMBLAVEO (aztreonam-avibactam) to treat adult patients with complicated intra-abdominal infections, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also approved for treating infections caused by aerobic Gram-negative organisms in adult patients with limited treatment options.
- In March 2024, Bristol Myers Squibb provided an update after the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program, assessing Zeposia (ozanimod) in adults with moderate to severe active Crohn’s disease. The study did not achieve its primary endpoint of clinical remission at Week 12. The safety profile of Zeposia in this study was consistent with that observed in earlier trials.
- In July 2023, Bayer and the Swiss Tropical and Public Health Institute (Swiss TPH) announced a collaboration to advance the clinical development of an active substance for treating humans infected with soil-transmitted helminths. This partnership comes after promising results from a Phase II study conducted by Swiss TPH and its partners in Tanzania, which focused on patients with whipworm (Trichuris trichiura) and hookworm (Ancylostoma duodenale and Necator americanus) infections.
